Your Source for Venture Capital and Private Equity Financings

Kyverna Therapeutics Closes $85M Series B

2022-01-27
EMERYVILLE, CA, Kyverna Therapeutics, a cell therapy company, has closed an oversubscribed $85M Series B financing round led by Northpond Ventures.
Kyverna Therapeutics, a cell therapy company engineering a new class of therapies for serious autoimmune diseases, has closed an oversubscribed $85 million Series B financing round led by Northpond Ventures.

Additional investors included the company's founding investors Westlake Village BioPartners, Vida Ventures, and Gilead Sciences, with new investors RTW Investments, LP, CAM Capital, Insight Partners, HealthCor, LYFE Capital, Intellia Therapeutics, Argentum Peak, Hudson Bay Capital, and jVen Capital.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000 startups and 5,000 VC investors


Featured Reading